[Comment] Expanding the therapeutic arsenal for paediatric ulcerative colitis

Interleukin-23 (IL-23) plays a pivotal role in the complex pathogenesis of both ulcerative colitis and Crohn's disease, making it a promising therapeutic target.1 Mirikizumab is a humanised IgG4 monoclonal antibody that selectively inhibits IL-23 by binding to its p19 subunit. The drug has been approved for moderate-to-severe adult ulcerative colitis; however, clinical trials in the paediatric population are still in earlier stages of development. In The Lancet Gastroenterology & Hepatology, Jess L Kaplan and colleagues report data from SHINE-1, the first phase 2 trial of mirikizumab in children with moderate-to-severe ulcerative colitis.